Skip to main content
U.S. flag

An official website of the United States government

Return to search results
💡 Advanced Search Tip

Search by organization or tag to find related datasets

Rheumatoid arthritis, gold therapy, contact allergy and blood cytokines

Published by National Institutes of Health | U.S. Department of Health & Human Services | Metadata Last Checked: September 06, 2025 | Last Modified: 2025-09-06
Objective To study the clinical and biochemical effects of a low starting dose for gold therapy in rheumatoid arthritis patients with a contact allergy to gold. Methods Serum cytokines were assayed before and 24 h after the first injection of gold sodium thiomalate (GSTM). Results Contact allergy to gold was found in 4 of 19 patients. Compared to gold-negative patients (starting dose: 10 mg GSTM), there was a larger increase in serum TNFalpha (p < 0.05), sTNF-R1 (NS), and IL-1 ra (p < 0.05) in gold-allergic patients. Conclusions Cytokines are released in blood by GSTM in RA patients with gold allergy. To minimize the risk of acute adverse reactions the starting dose of GSTM should be lowered to 5 mg. Alternatively, patients should be patch-tested before gold therapy; in test-positive cases, 5 mg is recommended as the first dose.

Find Related Datasets

Click any tag below to search for similar datasets

Complete Metadata

data.gov

An official website of the GSA's Technology Transformation Services

Looking for U.S. government information and services?
Visit USA.gov